Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hepatology

Treatment Options for Isolated PCLD

At a Glance

Treatment for Isolated PCLD focuses on managing physical symptoms caused by liver enlargement rather than fixing liver function. Options range from watchful waiting for asymptomatic patients to medications, surgical debulking, or liver transplantation for severe cases.

When it comes to Isolated Polycystic Liver Disease (PCLD), the goal of treatment is not to “fix” liver function—which is usually healthy—but to manage the physical symptoms caused by an enlarged liver. Your care team will likely use a tiered approach, moving from simple monitoring to more active treatments based on how much the liver is growing and how you feel [1][2].

The PCLD Treatment Framework

Disease Severity Common Symptoms Typical Management Strategy
Asymptomatic None; diagnosed incidentally Observation (Watchful Waiting)
Mild / Moderate Occasional pain, “fullness” Sclerotherapy or Somatostatin Analogues
Advanced Early satiety, malnutrition, severe pain Surgical Debulking (Fenestration or Resection)
Refractory Intractable symptoms, cachexia (wasting) Liver Transplantation

1. Observation (Watchful Waiting)

If you have no symptoms and your liver function tests are normal, the standard recommendation is periodic monitoring [3]. Many patients live their entire lives without needing any treatment beyond a routine ultrasound or MRI every 1 to 2 years to check for growth [4][3].

2. Medical Therapy: Somatostatin Analogues

If your liver is growing and causing discomfort, your doctor may prescribe somatostatin analogues (SSAs), such as octreotide or lanreotide [5][6]. These medications, usually given as monthly injections, work by lowering levels of certain hormones and signaling molecules (like cAMP) that fuel cyst growth [7][8].

  • Effectiveness: SSAs can modestly reduce liver volume (often by 5–10%) and, more importantly, slow down the rate of future growth [8][9].
  • Side Effects: Some patients experience digestive issues, weight loss, or a decrease in muscle mass while on these medications [10][11]. Importantly, SSAs carry a high risk of developing gallstones (cholelithiasis) and fatty stools (steatorrhea) due to changes in digestion and bile flow, which you should monitor for and discuss with your doctor [10].

3. Surgical and Interventional Procedures

When specific cysts or the overall size of the liver become too large to manage with medication, several procedures can “debulk” the liver to create more space in your abdomen.

  • Aspiration Sclerotherapy: This is a minimally invasive procedure where a doctor uses a needle to drain a “dominant” (large) cyst and then injects a hardening agent (like alcohol) to prevent it from refilling [12][13].
  • Cyst Fenestration: Often done laparoscopically, this involves “roofing” or popping multiple cysts so they drain into the abdominal cavity and shrink [14][15].
  • Partial Hepatectomy: In cases where the cysts are concentrated in one part of the liver, a surgeon may remove that entire segment [1][16]. This can provide dramatic and long-lasting relief because it removes a large volume of the liver while sparing the healthy tissue [17].

4. Liver Transplantation

Liver transplantation is the only cure for PCLD, but it is reserved for the most severe cases where all other treatments have failed [18][19].
Unlike patients with cirrhosis, PCLD patients often have a low MELD score (the typical ranking system for transplants) because their liver function is good [20]. Instead, they are considered for transplant based on “mass effect” complications, such as severe malnutrition (because the liver has crushed the stomach) or the inability to breathe properly [19][21]. In many regions, PCLD patients can receive “exception points” to help them move up the transplant list [18].

Because this is a major surgery, it is typically considered only when the patient’s quality of life is severely and permanently impaired [19][22].

Return to the Home Page.

Common questions in this guide

Am I a candidate for somatostatin analogues for my PCLD?
Doctors typically prescribe somatostatin analogues like octreotide or lanreotide if your liver is actively growing and causing discomfort. These monthly injections can help reduce liver volume and slow future cyst growth.
Can large liver cysts be treated without major surgery?
Yes, if you have a large, dominant cyst, it may be treated with aspiration sclerotherapy. This minimally invasive procedure involves draining the cyst with a needle and injecting a hardening agent to stop it from refilling.
What are the side effects of medications used for PCLD?
Somatostatin analogues can cause digestive issues, weight loss, and a decrease in muscle mass. They also carry a high risk of causing gallstones and fatty stools due to changes in digestion and bile flow.
How do patients with PCLD qualify for a liver transplant?
Because PCLD patients usually have normal liver function, they often have a low MELD score. They qualify for transplant based on exception points granted for severe physical complications like malnutrition or an inability to breathe properly.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my current liver volume and symptoms, am I a candidate for medical therapy with somatostatin analogues (octreotide/lanreotide)?
  2. 2.Do I have 'dominant' cysts that could be treated with aspiration sclerotherapy rather than a more invasive surgery?
  3. 3.If we consider surgery, is my disease localized enough for a partial hepatectomy, or is it too diffuse?
  4. 4.What are the long-term side effects of somatostatin analogues, particularly regarding the risk of gallstones or fatty stools?
  5. 5.How do we track my progression to know if I might eventually need to be evaluated for a liver transplant?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Operative Outcomes for Polycystic Liver Disease: Results of a Large Contemporary Series.

    Smith SR, Matar AJ, Polireddy K, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2023; (27(11)):2444-2450 doi:10.1007/s11605-023-05843-1.

    PMID: 37783909
  2. 2

    Key Aspects in the Nutritional Management of Polycystic Liver Disease Patients.

    Khan S, Di Cola S, Lai S, et al.

    Nutrients 2025; (17(14)) doi:10.3390/nu17142380.

    PMID: 40733005
  3. 3

    Apixaban Causing Hepatic Cystic Bleeding: A Rare but a Life-Threatening Complication.

    Shehi E, Fortuzi K, Ghazanfar H, et al.

    Case reports in gastroenterology 2021; (15(3)):904-909 doi:10.1159/000519276.

    PMID: 34720842
  4. 4

    Extrarenal Manifestations: Polycystic Liver Disease and Its Complications.

    Bugazia S, Hogan MC

    Advances in kidney disease and health 2023; (30(5)):440-453 doi:10.1053/j.akdh.2023.10.004.

    PMID: 37943238
  5. 5

    Polycystic liver disease: Evidence-based management and critical gaps in surgical decision-making.

    Florou E, Prachalias A, Srinivasan P

    American journal of surgery 2026; (254()):116856 doi:10.1016/j.amjsurg.2026.116856.

    PMID: 41671922
  6. 6

    Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases.

    Heinrich S, de Matos AMC, Colmenero J, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2026; (46(1)):e70451 doi:10.1111/liv.70451.

    PMID: 41328663
  7. 7

    TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.

    Masyuk TV, Masyuk AI, Lorenzo Pisarello M, et al.

    Hepatology (Baltimore, Md.) 2017; (66(4)):1197-1218 doi:10.1002/hep.29284.

    PMID: 28543567
  8. 8

    Combined liver-kidney transplantation for polycystic liver and kidney disease: analysis from the United Network for Organ Sharing dataset.

    Coquillard C, Berger J, Daily M, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2016; (36(7)):1018-25 doi:10.1111/liv.13041.

    PMID: 26663575
  9. 9

    Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

    van Aerts RMM, Kievit W, D'Agnolo HMA, et al.

    Gastroenterology 2019; (157(2)):481-491.e7 doi:10.1053/j.gastro.2019.04.018.

    PMID: 31022403
  10. 10

    Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.

    Neijenhuis MK, Gevers TJ, Nevens F, et al.

    Alimentary pharmacology & therapeutics 2015; (42(5)):591-8 doi:10.1111/apt.13301.

    PMID: 26129925
  11. 11

    The safety of available treatments options for neuroendocrine tumors.

    Faggiano A, Lo Calzo F, Pizza G, et al.

    Expert opinion on drug safety 2017; (16(10)):1149-1161 doi:10.1080/14740338.2017.1354984.

    PMID: 28705090
  12. 12

    Prediction of hepatic cyst recurrence after minocycline hydrochloride aspiration sclerotherapy using cyst computed tomography values.

    Iijima T, Suwabe T, Sumida K, et al.

    Hepatology research : the official journal of the Japan Society of Hepatology 2017; (47(5)):419-424 doi:10.1111/hepr.12763.

    PMID: 27316759
  13. 13

    CT-guided percutaneous aspiration and bleomycin sclerotherapy for symptomatic hepatic cysts: technique and three-year outcomes.

    Li L, Lao YH, Han QL

    Frontiers in medicine 2025; (12()):1687375 doi:10.3389/fmed.2025.1687375.

    PMID: 41322221
  14. 14

    Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis.

    Bernts LHP, Echternach SG, Kievit W, et al.

    Surgical endoscopy 2019; (33(3)):691-704 doi:10.1007/s00464-018-6490-8.

    PMID: 30334152
  15. 15

    Comparison of the Recurrence Rates of Nonparasitic Hepatic Cysts Treated With Laparoscopy or With Open Fenestration: A Meta-Analysis.

    Zhang JY, Liu Y, Liu HY, et al.

    Surgical laparoscopy, endoscopy & percutaneous techniques 2018; (28(2)):67-72 doi:10.1097/SLE.0000000000000516.

    PMID: 29528948
  16. 16

    Partial major hepatectomy with cyst fenestration for polycystic liver disease: Indications, short and long-term outcomes.

    Boillot O, Cayot B, Guillaud O, et al.

    Clinics and research in hepatology and gastroenterology 2021; (45(3)):101670 doi:10.1016/j.clinre.2021.101670.

    PMID: 33722781
  17. 17

    Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease.

    Bernts LHP, Neijenhuis MK, Edwards ME, et al.

    Surgery 2020; (168(1)):25-32 doi:10.1016/j.surg.2020.02.014.

    PMID: 32402542
  18. 18

    Liver transplantation in adult polycystic liver disease: the Ontario experience.

    Alsager M, Neong SF, Gandhi R, et al.

    BMC gastroenterology 2021; (21(1)):115 doi:10.1186/s12876-021-01703-x.

    PMID: 33750299
  19. 19

    Polycystic Kidney/Liver Disease.

    Roediger R, Dieterich D, Chanumolu P, Deshpande P

    Clinics in liver disease 2022; (26(2)):229-243 doi:10.1016/j.cld.2022.01.009.

    PMID: 35487607
  20. 20

    Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes.

    Rajoriya N, Tripathi D, Leithead JA, et al.

    World journal of gastroenterology 2016; (22(45)):9966-9973 doi:10.3748/wjg.v22.i45.9966.

    PMID: 28018103
  21. 21

    Treatment of polycystic liver disease. Update on the management.

    Aussilhou B, Dokmak S, Dondero F, et al.

    Journal of visceral surgery 2018; (155(6)):471-481 doi:10.1016/j.jviscsurg.2018.07.004.

    PMID: 30145049
  22. 22

    Evidence of nonsurgical treatment for polycystic liver disease.

    Yoo JJ, Jo HI, Jung EA, et al.

    Therapeutic advances in chronic disease 2022; (13()):20406223221112563 doi:10.1177/20406223221112563.

    PMID: 35898920

This page provides educational information on PCLD treatment options and does not replace professional medical advice. Always consult your hepatologist regarding your specific liver care plan.

Get notified when new evidence is published on Isolated polycystic liver disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.